The learning disability treatment market is set to reach US$ 30,493.1 million by 2027 from US$ 17,418.0 million in 2018, highlighting steady growth at a compounded annual growth rate (CAGR) of 6.5% during the forecast period from 2019 to 2027.
Children with learning disabilities have tremendous mental ability, but due to irregular impulses generated by the central nervous system, they suffer from altered behavior and lower cognitive skills. If diagnosed at an early stage, the proper medical intervention will improve the quality of life for the patient suffering from a learning disability.
Market Synopsis
Excellent therapeutic efficacy and rising popularity among psychiatrists drive the demand for stimulant and non-stimulant medication.
Stimulant and non-stimulant medications are leading the therapy segment for the learning disability treatment market. Psychoactive drugs such as Ritalin, Focalin, Dexedrine, and Vynase are prescribed for improving central nervous system activity by blocking the uptake of catecholamines such as dopamine and norepinephrine.
Non-stimulants are also prescribed to treat depression and anxiety in a few patients suffering from ADHD. In addition, assistive technology is gaining huge traction owing to its ability to provide cognitive behavioral therapy and occupational therapy in the form of learning applications and software to aid teachers in helping kids with dyslexia and dyspraxia.
A comprehensive evaluation test and critical assessment of underlying language skills result in an early diagnosis of dyslexia.
Dyslexia is reigning in the indications segment for the learning disability treatment market. According to research conducted by the International Dyslexia Association (IDA), the prevalence rate of dyslexia in children qualifying for special education is 6–7%. The core problem associated with dyslexia is difficulty in word recognition, reading and writing fluency, etc.
A comprehensive evaluation test and critical assessment of underlying language skills result in an early diagnosis of dyslexia and interventional therapy. Attention deficit hyperactivity disorder (ADHD) has a worldwide prevalence rate of 2.2%, with a higher occurrence in males in comparison to females.
Effective clinical guidelines have been designed by psychiatrists worldwide with an effective combination of pharmacological drugs and occupational and cognitive-behavioral therapy to treat ADHD effectively.
In North America, the market is being driven by the rising prevalence of ADHD and proactive government initiatives to promote awareness and treatment for mentally disabled children.
North America is presently dominating the regional segment of the learning disability treatment market, holding a market share of 32.5%. The major factor responsible for its outstanding market growth is the rising prevalence of attention deficit hyperactivity disorder (ADHD); as per the statistics provided by the American Psychiatric Association (APA), in 2016, approximately 6.1 million children were diagnosed with ADHD in North America.
Proactive government initiatives to promote awareness and treatment for mentally disabled children further bolster market growth. Europe represents a 29% market share on account of the rising prevalence of dyslexia across all age groups. According to the European Dyslexia Association (EDA) research, dyslexia affects between 9% and 12% of the population.
The Asia Pacific holds an 18.5% market share owing to the rampant growth in schools and institutes to treat children with learning disabilities and the significant rise in assistive technology focusing on the development of learning software and applications in compliance with occupational therapy.
Periods of History and Forecast
This research report presents the analysis of each segment from 2017 to 2027, considering 2018 as the base year for the research. In addition, the compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2019 to 2027.
Report Scope by Segments
The market segmentation for the report's scope is done by therapy, indication, and geography.
According to Indication (2017-2027; US$ Mn)
Attention Deficit Hyperactivity Disorder (ADHD)
Dyslexia
Dyspraxia
Others
Geography Segment (US$ Mn; 2017-2027)
North America (U.S., Canada)
Europe (U.K., Germany, rest of Europe)
Asia Pacific (China, Japan, and the Rest of Asia Pacific)
Latin America (Brazil, Mexico, and the Rest of Latin America)
the Middle East and Africa (GCC and the rest of the MEA)
IT-Healthcare, in collaboration with pharmaceutical companies actively participating in the learning disability treatment market, includes CogniFit, Eli Lilly & Company, Forest Laboratories, Inc., IMSE, Novartis AG, Pfizer, Inc., Shire Plc., Therapro, Inc., Tumble N' Dots, Inc., and Texthelp Ltd.
Recent News
A link between disrupted enzymes and intellectual disability has been discovered.
A study reveals how intellectual disability is caused by a rare genetic mutation in the enzyme called CaMKIIalpha. The P212L mutation leads to dramatically more activation and less inhibition of CaMKIIalpha, potentially leading to a potential treatment for intellectual disability. ScienceDaily
Estimating individual treatment effects on disability progression in multiple sclerosis using deep learning
In this study, predictive enrichment using a predictive deep-learning model increased the number of patients responding to medications in clinical trials by preferentially enrolling those predicted to have the best response. The model is validated by testing responses to anti-CD20 antibodies and laquinimod, which combined have an increased response rate of 37% over placebo based on biomarkers. Source: Nature
Frequently Asked Questions:
The market for OLearning Disability Treatment is expected to reach US$ 30,493.1 Mn by 2027.
The Learning Disability Treatment Market is expected to see significant CAGR growth over the coming years, at 6.5%.
The report is forecasted from 2019-2027.
The base year of this report is 2018.
Eli Lilly & Company, CogniFit, Forest Laboratories, Inc., IMSE, Novartis AG, Pfizer, Inc.are some of the major players in the global market.
